CRISPR Therapeutics’ gene editing therapy reduces bad cholesterol and triglycerides by as much as 80%

Gene Modification, Clustered Regularly Interspaced Short Palindromic Repeats, Triglycerides, LDL Cholesterol Lipoproteins, In Vivo, CTX310, Clinical Trials, cholesterol, Genes

‘Now is not the time to retreat’: BMS CEO blasts Trump admin tariffs, health reforms amid $40B US investment pledge

Bristol Myers Squibb, Trump tariffs, pharmaceutical manufacturing, domestic investment, pharmaceutical industry, US manufacturing, healthcare reform, pharmaceutical tariffs